Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis : Results From a Five-Year Follow-Up Study

DSpace/Manakin Repository